Jennifer L McNeer, MD

Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children's Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children's Hospital.

After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children's Memorial Hospital (now Lurie Children's Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children's Memorial Hospital, and during her fellowship earned a master's degree in clinical investigation at Northwestern University Feinberg School of Medicine.

Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children's Oncology Group.

Dr. McNeer's clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children's Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.

Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life.